These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 34952628)

  • 21. Clinical features and prognosis according to genomic mutations in primary and metastatic lesions of non-small-cell lung cancer.
    Zhang W; Han W; Yu B; Zhao X; Lu G; Wu W; Zhang Y
    Thorac Cancer; 2022 Jun; 13(11):1642-1650. PubMed ID: 35466584
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Survival analysis for non-squamous NSCLC patients harbored STK11 or KEAP1 mutation receiving atezolizumab.
    Shang X; Li Z; Sun J; Zhao C; Lin J; Wang H
    Lung Cancer; 2021 Apr; 154():105-112. PubMed ID: 33640623
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of KEAP1/NFE2L2/CUL3 mutations on duration of response to EGFR tyrosine kinase inhibitors in EGFR mutated non-small cell lung cancer.
    Hellyer JA; Stehr H; Das M; Padda SK; Ramchandran K; Neal JW; Diehn M; Wakelee HA
    Lung Cancer; 2019 Aug; 134():42-45. PubMed ID: 31319993
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Alterations of LKB1 and KRAS and risk of brain metastasis: comprehensive characterization by mutation analysis, copy number, and gene expression in non-small-cell lung carcinoma.
    Zhao N; Wilkerson MD; Shah U; Yin X; Wang A; Hayward MC; Roberts P; Lee CB; Parsons AM; Thorne LB; Haithcock BE; Grilley-Olson JE; Stinchcombe TE; Funkhouser WK; Wong KK; Sharpless NE; Hayes DN
    Lung Cancer; 2014 Nov; 86(2):255-61. PubMed ID: 25224251
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multiomics profiling of primary lung cancers and distant metastases reveals immunosuppression as a common characteristic of tumor cells with metastatic plasticity.
    Lee WC; Reuben A; Hu X; McGranahan N; Chen R; Jalali A; Negrao MV; Hubert SM; Tang C; Wu CC; Lucas AS; Roh W; Suda K; Kim J; Tan AC; Peng DH; Lu W; Tang X; Chow CW; Fujimoto J; Behrens C; Kalhor N; Fukumura K; Coyle M; Thornton R; Gumbs C; Li J; Wu CJ; Little L; Roarty E; Song X; Lee JJ; Sulman EP; Rao G; Swisher S; Diao L; Wang J; Heymach JV; Huse JT; Scheet P; Wistuba II; Gibbons DL; Futreal PA; Zhang J; Gomez D; Zhang J
    Genome Biol; 2020 Nov; 21(1):271. PubMed ID: 33148332
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Acquirement of DNA copy number variations in non-small cell lung cancer metastasis to the brain.
    Li F; Sun L; Zhang S
    Oncol Rep; 2015 Oct; 34(4):1701-7. PubMed ID: 26259861
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Breast cancer metastasis suppressor-1 promoter methylation in cell-free DNA provides prognostic information in non-small cell lung cancer.
    Balgkouranidou I; Chimonidou M; Milaki G; Tsarouxa EG; Kakolyris S; Welch DR; Georgoulias V; Lianidou ES
    Br J Cancer; 2014 Apr; 110(8):2054-62. PubMed ID: 24642624
    [TBL] [Abstract][Full Text] [Related]  

  • 28. EGFR mutation status of paired cerebrospinal fluid and plasma samples in EGFR mutant non-small cell lung cancer with leptomeningeal metastases.
    Zhao J; Ye X; Xu Y; Chen M; Zhong W; Sun Y; Yang Z; Zhu G; Gu Y; Wang M
    Cancer Chemother Pharmacol; 2016 Dec; 78(6):1305-1310. PubMed ID: 27770237
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sensitive methods for screening of the MEK1 gene mutations in patients with central nervous system metastases of non-small cell lung cancer.
    Nicoś M; Krawczyk P; Jarosz B; Sawicki M; Michnar M; Trojanowski T; Milanowski J
    Clin Transl Oncol; 2016 Oct; 18(10):1039-43. PubMed ID: 26860843
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Potential utility of longitudinal somatic mutation and methylation profiling for predicting molecular residual disease in postoperative non-small cell lung cancer patients.
    Li H; Ma ZL; Li B; Pan YJ; Xiang JQ; Zhang YW; Sun YH; Hou T; Lizaso A; Chen Y; Li X; Hu H
    Cancer Med; 2021 Dec; 10(23):8377-8386. PubMed ID: 34664796
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cerebrospinal fluid circulating tumor DNA depicts profiling of brain metastasis in NSCLC.
    Wu J; Liu Z; Huang T; Wang Y; Song MM; Song T; Long G; Zhang X; Li X; Zhang L
    Mol Oncol; 2023 May; 17(5):810-824. PubMed ID: 36495130
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genetic mutations associated with lung cancer metastasis to the brain.
    Aljohani HM; Aittaleb M; Furgason JM; Amaya P; Deeb A; Chalmers JJ; Bahassi EM
    Mutagenesis; 2018 Apr; 33(2):137-145. PubMed ID: 29474635
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genome-wide combination profiling of DNA copy number and methylation for deciphering biomarkers in non-small cell lung cancer patients.
    Son JW; Jeong KJ; Jean WS; Park SY; Jheon S; Cho HM; Park CG; Lee HY; Kang J
    Cancer Lett; 2011 Dec; 311(1):29-37. PubMed ID: 21757291
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of Tumor Mutational Burden and Gene Alterations Associated with Radiation Response on Outcomes of Postoperative Radiation Therapy in Non-Small Cell Lung Cancer.
    Shaverdian N; Shepherd AF; Li X; Offin M; Lengel HB; Gelblum DY; Wu AJ; Simone CB; Rimner A; Jones DR; Chaft JE; Riaz N; Gomez DR
    Int J Radiat Oncol Biol Phys; 2022 Jun; 113(2):335-344. PubMed ID: 35157996
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genomic Characteristics and the Potential Clinical Implications in Oligometastatic Non-Small Cell Lung Cancer.
    Liao R; Chen K; Li J; He H; Yi G; Huang M; Chen R; Shen L; Zhang X; Xu Z; Yang Z; Peng Y
    Cancer Res Treat; 2023 Jul; 55(3):814-831. PubMed ID: 36634615
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative analysis of the tumor immune-microenvironment of primary and brain metastases of non-small-cell lung cancer reveals organ-specific and EGFR mutation-dependent unique immune landscape.
    Song SG; Kim S; Koh J; Yim J; Han B; Kim YA; Jeon YK; Chung DH
    Cancer Immunol Immunother; 2021 Jul; 70(7):2035-2048. PubMed ID: 33420630
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Frequent epigenetic inactivation of deleted in lung and esophageal cancer 1 gene by promoter methylation in non-small-cell lung cancer.
    Zhang Y; Miao Y; Yi J; Wang R; Chen L
    Clin Lung Cancer; 2010 Jul; 11(4):264-70. PubMed ID: 20630829
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Next-generation sequencing reveals high concordance of recurrent somatic alterations between primary tumor and metastases from patients with non-small-cell lung cancer.
    Vignot S; Frampton GM; Soria JC; Yelensky R; Commo F; Brambilla C; Palmer G; Moro-Sibilot D; Ross JS; Cronin MT; André F; Stephens PJ; Lazar V; Miller VA; Brambilla E
    J Clin Oncol; 2013 Jun; 31(17):2167-72. PubMed ID: 23630207
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Methylation of multiple genes as a candidate biomarker in non-small cell lung cancer.
    Zhang Y; Wang R; Song H; Huang G; Yi J; Zheng Y; Wang J; Chen L
    Cancer Lett; 2011 Apr; 303(1):21-8. PubMed ID: 21255913
    [TBL] [Abstract][Full Text] [Related]  

  • 40. KEAP1/NFE2L2 Pathway Signature Outperforms KEAP1/NFE2L2 Mutation Status and Reveals Alternative Pathway-Activating Mutations in NSCLC.
    Arolt C; Dugan M; Wild R; Richartz V; Holz B; Scheel AH; Brägelmann J; Wagener-Ryczek S; Merkelbach-Bruse S; Wolf J; Buettner R; Catanzariti L; Scheffler M; Hillmer AM
    J Thorac Oncol; 2023 Nov; 18(11):1550-1567. PubMed ID: 37473958
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.